Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma

Chimeric antigen receptor T cells (CAR-T cell) targeting CD19 are effective against several subtypes of CD19-expressing hematologic malignancies. Centralized manufacturing has allowed rapid expansion of this cellular therapy, but it may be associated with treatment delays due to the required logisti...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Zachary, Roe, Anne, Sharma, Ashish Arunkumar, Lopes, Filipa Blasco Tavares Pereira, Talla, Aarthi, Kleinsorge-Block, Sarah, Zamborsky, Kayla, Schiavone, Jennifer, Manjappa, Shivaprasad, Schauner, Robert, Lee, Grace, Liu, Ruifu, Caimi, Paolo F., Xiong, Ying, Krueger, Winfried, Worden, Andrew, Kadan, Mike, Schneider, Dina, Orentas, Rimas, Dropulic, Boro, Sekaly, Rafick-Pierre, de Lima, Marcos, Wald, David N., Reese, Jane S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427107/
https://www.ncbi.nlm.nih.gov/pubmed/32849651
http://dx.doi.org/10.3389/fimmu.2020.01941

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427107/
https://www.ncbi.nlm.nih.gov/pubmed/32849651
http://dx.doi.org/10.3389/fimmu.2020.01941

Ejemplares similares